Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA

Tuesday, January 7, 2020 Press Release
Email Print This Page Comment bookmark
Font : A-A+

SAN FRANCISCO, Jan. 7, 2020 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 13, 2020 at 2:30 p.m. Pacific Time.

The presentation will be accessible via a Webcast through a link posted on the Investors, Events Calendar section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. In addition, the company will webcast the Q&A breakout session immediately following its presentation at 3:00 p.m. Pacific Time. This Webcast will be available for replay until February 21, 2020.

About Nektar TherapeuticsNektar Therapeutics is a research-based, development-stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. Our R&D pipeline of new investigational medicines includes treatments for cancer, autoimmune disease and chronic pain. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new therapeutic candidates. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Contacts:

For Investors:Vivian Wu of Nektar Therapeutics628-895-0661

For Media:Jodi Sievers of Nektar Therapeutics415-482-5593

Dan Budwick of 1AB973-271-6085dan@1abmedia.com

 

Cision View original content:http://www.prnewswire.com/news-releases/nektar-therapeutics-president-and-ceo-howard-robin-to-present-at-the-38th-annual-jp-morgan-healthcare-conference-in-san-francisco-ca-300982385.html

SOURCE Nektar Therapeutics



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Premium Membership Benefits

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store